Effects of metformin and statins on outcomes in men with castration-resistant metastatic prostate cancer: Secondary analysis of COU-AA-301 and COU-AA-302.

ABSTRACT:

Background

The associations of metformin and statins with overall survival (OS) and prostate specific antigen response rate (PSA-RR) in trials in metastatic castration-resistant prostate cancer remain unclear.

Objective

To determine whether metformin or statins ± abiraterone acetate plus prednisone/prednisolone (AAP) influence OS and PSA-RR.

Design, setting and participant

COU-AA-301 and COU-AA-302 patients were stratified by metformin and statin use. Cox proportional hazards models were used to estimate hazards ratio (HR) stratified by concomitant medications, and a random effects model was used to pool HR. We compared PSA-RR using Chi χ² test.

Results

In COU-AA-301-AAP, metformin was associated with improved PSA-RR (41.1% versus 28.6%) but not prol

SUBMITTER: Wilson BE 

PROVIDER: S-EPMC9949683 | biostudies-literature | 2022 Jul

REPOSITORIES: biostudies-literature